188 related articles for article (PubMed ID: 38095483)
1. Onconephrology: mitigation of renal injury in chemotherapy administration.
Selamet U; Ahdoot RS; Salasnek R; Abdelnour L; Hanna RM
Curr Opin Nephrol Hypertens; 2024 Mar; 33(2):257-266. PubMed ID: 38095483
[TBL] [Abstract][Full Text] [Related]
2. Onconephrology: The intersections between the kidney and cancer.
Rosner MH; Jhaveri KD; McMahon BA; Perazella MA
CA Cancer J Clin; 2021 Jan; 71(1):47-77. PubMed ID: 32853404
[TBL] [Abstract][Full Text] [Related]
3. Onconephrology: Core Curriculum 2023.
Yarandi N; Shirali AC
Am J Kidney Dis; 2023 Dec; 82(6):743-761. PubMed ID: 37855786
[TBL] [Abstract][Full Text] [Related]
4. Perspectives From an Onconephrology Interest Group: Conference Report.
Kitchlu A; Chan CT; Leung N; Chen S; Latcha S; Tam P
Can J Kidney Health Dis; 2020; 7():2054358120962589. PubMed ID: 33117547
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy-Related Acute Kidney Injury.
Manohar S; Jhaveri KD; Perazella MA
Adv Chronic Kidney Dis; 2021 Sep; 28(5):429-437.e1. PubMed ID: 35190109
[TBL] [Abstract][Full Text] [Related]
6. Onconephrology: A New Challenge for the Nephrologist.
Fofi C; Festuccia F
Contrib Nephrol; 2021; 199():91-105. PubMed ID: 34375977
[TBL] [Abstract][Full Text] [Related]
7. Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists.
Matsubara T; Yokoi H; Yamada H; Yanagita M
Int J Clin Oncol; 2023 May; 28(5):625-636. PubMed ID: 36872414
[TBL] [Abstract][Full Text] [Related]
8. Onconephrology: the latest frontier in the war against kidney disease.
Salahudeen AK; Bonventre JV
J Am Soc Nephrol; 2013 Jan; 24(1):26-30. PubMed ID: 23138480
[TBL] [Abstract][Full Text] [Related]
9. The Link Between Conventional and Novel Anti-Cancer Therapeutics with Thrombotic Microangiopathy.
Cervantes CE; Kant S; Atta MG
Drug Metab Lett; 2021; 14(2):97-105. PubMed ID: 34279209
[TBL] [Abstract][Full Text] [Related]
10. Onco-Nephrology: Cancer, chemotherapy and kidney.
de Francisco ALM; Macía M; Alonso F; García P; Gutierrez E; Quintana LF; Quiroga B; Torregrosa I
Nefrologia (Engl Ed); 2019; 39(5):473-481. PubMed ID: 30929891
[TBL] [Abstract][Full Text] [Related]
11. Onconephrology: Update in Anticancer Drug-Related Nephrotoxicity.
García-Carro C; Draibe J; Soler MJ
Nephron; 2023; 147(2):65-77. PubMed ID: 35717937
[TBL] [Abstract][Full Text] [Related]
12. Adverse renal effects of check-point inhibitors (ICI) in cancer patients: Recommendations of the Onco-nephrology Working Group of the Spanish Society of Nephrology.
Alonso F; Martín de Francisco ÁLM; Auñón P; García-Carro C; García P; Gutiérrez E; Mcía M; Quintana LF; Quiroga B; Soler MJ; Torregrosa I;
Nefrologia (Engl Ed); 2023; 43(5):622-635. PubMed ID: 38000944
[TBL] [Abstract][Full Text] [Related]
13. [Ten Years of Onconephrology].
Cosmai L
G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007821
[TBL] [Abstract][Full Text] [Related]
14. Glomerular diseases and cancer: evaluation of underlying malignancy.
Pani A; Porta C; Cosmai L; Melis P; Floris M; Piras D; Gallieni M; Rosner M; Ponticelli C
J Nephrol; 2016 Apr; 29(2):143-152. PubMed ID: 26498294
[TBL] [Abstract][Full Text] [Related]
15. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine.
Capasso A; Benigni A; Capitanio U; Danesh FR; Di Marzo V; Gesualdo L; Grandaliano G; Jaimes EA; Malyszko J; Perazella MA; Qian Q; Ronco P; Rosner MH; Trepiccione F; Viggiano D; Zoccali C; Capasso G;
Kidney Int; 2019 Sep; 96(3):555-567. PubMed ID: 31445584
[TBL] [Abstract][Full Text] [Related]
16. Onconephrology.
Kala J; Finkel KW
Crit Care Clin; 2021 Apr; 37(2):365-384. PubMed ID: 33752861
[TBL] [Abstract][Full Text] [Related]
17. Nephrotoxicity of anticancer treatment.
Malyszko J; Kozlowska K; Kozlowski L; Malyszko J
Nephrol Dial Transplant; 2017 Jun; 32(6):924-936. PubMed ID: 28339935
[TBL] [Abstract][Full Text] [Related]
18. Onco-nephrology: renal toxicities of chemotherapeutic agents.
Perazella MA
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1713-21. PubMed ID: 22879440
[TBL] [Abstract][Full Text] [Related]
19. Current Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.
Tonooka A; Ohashi R
J Nippon Med Sch; 2022 May; 89(2):128-138. PubMed ID: 34840210
[TBL] [Abstract][Full Text] [Related]
20. Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.
Piscitani L; Sirolli V; Di Liberato L; Morroni M; Bonomini M
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
